Hikma Pharmaceuticals PLC
HKMPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,127,000 | $2,875,000 | $2,517,000 | $2,553,000 |
| % Growth | 8.8% | 14.2% | -1.4% | – |
| Cost of Goods Sold | $1,712,000 | $1,468,000 | $1,252,000 | $1,252,000 |
| Gross Profit | $1,415,000 | $1,407,000 | $1,265,000 | $1,301,000 |
| % Margin | 45.3% | 48.9% | 50.3% | 51% |
| R&D Expenses | $141,000 | $149,000 | $144,000 | $143,000 |
| G&A Expenses | $568,000 | $638,000 | $509,000 | $488,000 |
| SG&A Expenses | $568,000 | $632,000 | $509,000 | $488,000 |
| Sales & Mktg Exp. | $0 | -$6,000 | $0 | $0 |
| Other Operating Expenses | $94,000 | $259,000 | $323,000 | $88,000 |
| Operating Expenses | $803,000 | $1,040,000 | $976,000 | $719,000 |
| Operating Income | $612,000 | $367,000 | $282,000 | $582,000 |
| % Margin | 19.6% | 12.8% | 11.2% | 22.8% |
| Other Income/Exp. Net | -$157,000 | -$86,000 | -$49,000 | -$38,000 |
| Pre-Tax Income | $455,000 | $281,000 | $233,000 | $544,000 |
| Tax Expense | $93,000 | $89,000 | $42,000 | $124,000 |
| Net Income | $359,000 | $190,000 | $188,000 | $421,000 |
| % Margin | 11.5% | 6.6% | 7.5% | 16.5% |
| EPS | 1.62 | 0.85 | 0.84 | 1.82 |
| % Growth | 90.6% | 1.2% | -53.8% | – |
| EPS Diluted | 1.61 | 0.85 | 0.84 | 1.81 |
| Weighted Avg Shares Out | 221,333 | 223,529 | 223,728 | 231,000 |
| Weighted Avg Shares Out Dil | 223,493 | 222,369 | 225,000 | 233,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,833 | $7,169 | $2,945 | $983 |
| Interest Expense | $75,000 | $89,096 | $68,728 | $55,043 |
| Depreciation & Amortization | $179,000 | $172,000 | $193,000 | $144,000 |
| EBITDA | $787,000 | $791,000 | $691,000 | $705,000 |
| % Margin | 25.2% | 27.5% | 27.5% | 27.6% |